An anthracycline antibiotic that has formula C27H29NO11.
Chemical ID:
MESH:D004317
Note: Use of the qualifier "multiple interactions" designates that the annotated interaction
is comprised of a complex set of reactions and/or regulatory events, possibly involving
additional chemicals and/or gene products.
ABCC1 affects the susceptibility to Doxorubicin; ABCC1 mRNA affects the susceptibility to Doxorubicin; ABCC1 protein affects the susceptibility to Doxorubicin
ABCC1 gene results in decreased susceptibility to Doxorubicin; ABCC1 protein results in decreased susceptibility to Doxorubicin; ABCC1 results in decreased susceptibility to Doxorubicin
[copper (N-2-hydroxyacetophenone)glycinate results in decreased expression of ABCC1 protein] which results in increased susceptibility to Doxorubicin; ABCC1 gene mutant form promotes the reaction [Doxorubicin results in increased cleavage of CASP3 protein]; ABCC1 gene mutant form promotes the reaction [Doxorubicin results in increased cleavage of PARP1 protein]; ABCC1 gene mutant form promotes the reaction [Doxorubicin results in increased expression of GCLC protein]; ABCC1 gene mutant form promotes the reaction [Doxorubicin results in increased expression of GCLM protein]; Doxorubicin inhibits the reaction [Lovastatin results in increased expression of ABCC1 mRNA]; Doxorubicin promotes the reaction [ABCC1 gene mutant form results in decreased expression of SOD3 mRNA]; Doxorubicin promotes the reaction [ABCC1 gene mutant form results in decreased expression of SOD3 protein]
[[Resveratrol co-treated with Doxorubicin] results in decreased expression of ABCC1 mRNA] which results in increased uptake of Doxorubicin; [Bortezomib co-treated with Doxorubicin] results in decreased expression of ABCC1 protein; [Doxorubicin co-treated with IL6 protein] results in increased expression of ABCC1 protein; [Doxorubicin results in decreased expression of ABCC1 mRNA] which results in increased susceptibility to Indomethacin; [Estradiol results in increased expression of ABCC1 mRNA] which results in increased susceptibility to Doxorubicin; [Glycyrrhetinic Acid affects the activity of ABCC1 protein] which affects the susceptibility to Doxorubicin; [MYCN protein affects the expression of ABCC1 mRNA] which affects the susceptibility to Doxorubicin; [Pentoxifylline co-treated with Doxorubicin] results in decreased expression of ABCC1 protein; [Resveratrol co-treated with Doxorubicin] results in decreased expression of ABCC1 mRNA; [Resveratrol results in decreased expression of ABCC1] which results in increased uptake of Doxorubicin; Acetylcysteine promotes the reaction [ABCC1 protein results in decreased susceptibility to Doxorubicin]; Buthionine Sulfoximine analog inhibits the reaction [Acetylcysteine promotes the reaction [ABCC1 protein results in decreased susceptibility to Doxorubicin]]; buthionine sulfoximine ethyl ester promotes the reaction [ABCC1 protein results in increased susceptibility to Doxorubicin]; Doxorubicin inhibits the reaction [ABCC1 protein affects the transport of Vincristine]; Doxorubicin promotes the reaction [JUN protein binds to ABCC1 promoter]; epigallocatechin gallate affects the reaction [Doxorubicin affects the expression of ABCC1 protein]; GCLC protein inhibits the reaction [ABCC1 protein results in decreased susceptibility to Doxorubicin]; Haloperidol inhibits the reaction [ABCC1 protein results in decreased susceptibility to Doxorubicin]; Heparin affects the reaction [ABCC1 protein affects the transport of Doxorubicin]; HIF1A protein affects the reaction [[Doxorubicin co-treated with IL6 protein] results in increased expression of ABCC1 protein]; Indomethacin inhibits the reaction [ABCC1 protein results in decreased susceptibility to Doxorubicin]; Verapamil inhibits the reaction [ABCC1 protein results in decreased susceptibility to Doxorubicin]; verlukast inhibits the reaction [ABCC1 protein results in decreased susceptibility to Doxorubicin]
